Latest Interim Results News

Vicinity Centres has reaffirmed its FY27 earnings targets after a resilient first quarter, with occupancy steady at 99.6%, leasing spreads widening to 5.1% and portfolio sales rising 3.0%. The AGM also marked the retirement of chairman Trevor Gerber and director Tim Hammon.

Vicinity Centres has reaffirmed its FY27 earnings guidance after a resilient first quarter, with occupancy steady at 99.6%, leasing spreads widening to 5.1% and total portfolio sales rising 3.0%. The AGM also marked Trevor Gerber’s retirement as chairman and the formal leadership transition to Patrick Allaway.

Accordant Group lifted first-half revenue 8% to NZ$88.5 million and cut its net loss to NZ$234,000, while reducing net bank debt by NZ$7 million since March. The staffing group still has a long way to go before returning to profit or restoring dividends.

Resonance Health has secured an oversubscribed $6.0 million placement to fund MRI endpoint expansion, new TrialsWest sites and development of its non-invasive liver fibrosis device. The raise lifts pro forma net cash to $7.9 million, but the most consequential project remains an investigational technology backed by a small preliminary dataset.

Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.

Djerriwarrh Investments has declared a fully franked first-quarter FY27 dividend of 3.75 cents per share and is targeting the same payment for the second quarter. The second distribution remains subject to market conditions and final Board approval.

Data#3 expects first-half FY27 profit before tax to rise more than 40% year on year, with gross profit also tracking more than 15% higher. The stronger result will be helped by large transactions, infrastructure activity and a temporary interest income boost, but the company expects earnings to be weighted toward the first half.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.

Paradigm Biopharmaceuticals has secured a voluntary suspension of its ASX securities while it prepares to release interim analysis results from its PARA_OA_012 Phase 3 trial. The announcement gives no indication whether the clinical readout is favourable or unfavourable, with trading potentially resuming on 28 September subject to ASX approval.

Cygnus Metals receives conditional TSX listing approval for Central Asia Metals shares amid unchanged positive expert opinion on the acquisition scheme.

Avecho has resumed enrolment for the last stage of its pivotal Phase III trial of a TPM®-enhanced CBD capsule for insomnia, following a unanimous Data Monitoring Board recommendation to continue without expanding the sample size.

Sky Network Television Limited posted a robust FY26 with 9% revenue growth, a 45% dividend increase, and secured major sports rights through 2034, underpinned by the integration of Sky Free.